Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC).

被引：0

作者：

Ozguroglu, Mustafa ^{[1
]}

Alva, Ajjai Shivaram ^{[2
]}

Csoszi, Tibor ^{[3
]}

Matsubara, Nobuaki ^{[4
]}

Geczi, Lajos ^{[5
]}

Cheng, Susanna Y. ^{[6
]}

Fradet, Yves ^{[7
]}

Oudard, Stephane ^{[8
]}

Vulsteke, Christof ^{[9
]}

Morales-Barrera, Rafael ^{[10
]}

Flechon, Aude ^{[11
]}

Gunduz, Seyda ^{[12
]}

Loriot, Yohann ^{[13
]}

Rodriguez-Vida, Alejo ^{[14
]}

Mamtani, Ronac ^{[15
]}

Yu, Evan Y. ^{[16
]}

Nam, Kijoeng ^{[17
]}

Imai, Kentaro ^{[17
]}

Moreno, Blanca Homet ^{[17
]}

Powles, Thomas ^{[18
]}

机构：

[1] Istanbul Univ Cerrahpasa, Cerrahpasa Med Sch, Istanbul, Turkey

[2] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA

[3] Hetenyi G Korhaz, Szolnok, Hungary

[4] Natl Canc Ctr Hosp East, Div Breast & Med Oncol, Chiba, Japan

[5] Natl Inst Oncol, Budapest, Hungary

[6] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada

[7] Univ Laval, CHU Quebec, Quebec City, PQ, Canada

[8] Univ Paris, Hop Europeen Georges Pompidou, AP HP, Dept Oncol, Paris, France

[9] Univ Antwerp, Integrated Canc Ctr Ghent, Ctr Oncol Res CORE, Ghent, Belgium

[10] Vall dHebron Inst Oncol, Barcelona, Spain

[11] Ctr Leon Berard, Dept Med Oncol, Lyon, France

[12] Akdeniz Univ, Antalya, Turkey

[13] Univ Paris Saclay, Inst Gustave Roussy, Dept Canc Med, Villejuif, France

[14] Hosp del Mar Res Inst, Dept Med Oncol, Barcelona, Spain

[15] Univ Penn, Philadelphia, PA 19104 USA

[16] Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA

[17] Merck & Co Inc, Kenilworth, NJ USA

[18] Queen Mary Univ London, Barts Canc Inst, Barts Expt Canc Med Ctr, London, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期

关键词：

D O I：

10.1200/JCO.2021.39.6_suppl.448

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

448

引用

页数：4

共 50 条

[1] Impact of subsequent therapy on survival in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as first-line therapy for advanced urothelial carcinoma (UC).
Alva, Ajjai Shivaram
Csoszi, Tibor
Ozguroglu, Mustafa
Matsubara, Nobuaki
Geczi, Lajos
Cheng, Susanna Y.
Fradet, Yves
Oudard, Stephane
Vulsteke, Christof
Morales-Barrera, Rafael
Flechon, Aude
Gunduz, Seyda
Loriot, Yohann
Rodriguez-Vida, Alejo
Mamtani, Ronac
Yu, Evan Y.
Nam, Kijoeng
Imai, Kentaro
Moreno, Blanca Homet
Powles, Thomas
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[2] 1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361.
Powles, Thomas
Csoszi, Tibor
Ozguroglu, Mustafa
Matsubara, Nobuaki
Geczi, Lajos
Cheng, Susanna Y.
Fradet, Yves
Oudard, Stephane
Vulsteke, Christof
Morales-Barrera, Rafael
Flechon, Aude
Gunduz, Seyda
Loriot, Yohann
Rodriguez-Vida, Alejo
Mamtani, Ronac
Yu, Evan Y.
Nam, Kijoeng
Imai, Kentaro
Moreno, Blanca Homet
Alva, Ajjai Shivaram
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[3] Association of TMB and PD-L1 with efficacy of first-line pembrolizumab (pembro) or pembro plus chemotherapy (chemo) versus chemo in patients (pts) with advanced urothelial carcinoma (UC) from KEYNOTE-361.
Morales-Barrera, Rafael
Powles, Thomas
Ozguroglu, Mustafa
Csoszi, Tibor
Loriot, Yohann
Flechon, Aude
Matsubara, Nobuaki
Rodriguez-Vida, Alejo
Geczi, Lajos
Cheng, Susanna Y.
Fradet, Yves
Oudard, Stephane
Gunduz, Seyda
Ma, Junshui
Rajasagi, Mohini
Vajdi, Amir
Cristescu, Razvan
Imai, Kentaro
Moreno, Blanca Homet
Alva, Ajjai Shivaram
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[4] Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer
Powles, Thomas
Gschwend, Juergen E.
Loriot, Yohann
Bellmunt, Joaquim
Geczi, Lajos
Vulsteke, Christof
Abdelsalam, Mahmoud
Gafanov, Rustem
Bae, Woo Kyun
Revesz, Janos
Yamamoto, Yoshiaki
Anido, Urbano
Su, Wen-Pin
Fleming, Mark T.
Markus, Maurice
Feng, Dai
Poehlein, Christian Heinrich
Alva, Ajjai
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[5] Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361
Alva, A.
Csoszi, T.
Ozguroglu, M.
Matsubara, N.
Geczi, L.
Cheng, S. Y-S.
Fradet, Y.
Oudard, S.
Vulsteke, C.
Morales Barrera, R.
Flechon, A.
Gunduz, S.
Loriot, Y.
Rodriguez-Vida, A.
Mamtani, R.
Yu, E. Y.
Nam, K.
Imai, K.
Moreno, B. H.
Powles, T. B.
ANNALS OF ONCOLOGY, 2020, 31 : S1155 - S1155
[6] Post-hoc analysis of long-term outcomes in patients with CR, PR, or SD to pembrolizumab (pembro) or platinum-based chemotherapy (chemo) as 1L therapy for advanced urothelial carcinoma (UC) in KEYNOTE-361.
Loriot, Yohann
Alva, Ajjai Shivaram
Csoszi, Tibor
Ozguroglu, Mustafa
Matsubara, Nobuaki
Geczi, Lajos
Cheng, Susanna Y.
Fradet, Yves
Oudard, Stephane
Vulsteke, Christof
Morales-Barrera, Rafael
Flechon, Aude
Gunduz, Seyda
Rodriguez-Vida, Alejo
Mamtani, Ronac
Yu, Evan Y.
Liu Chih-Chin
Imai, Kentaro
Moreno, Blanca Homet
Powles, Thomas
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[7] Pembrolizumab (pembro) 1 chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407
Paz-Ares, L.
Vicente, D.
Tafreshi, A.
Robinson, A.
Soto Parra, H.
Mazieres, J.
Hermes, B.
Cicin, I.
Medgyasszay, B.
Beatrix, B.
Rodriguez Cid, J.
Okamoto, I.
Lee, S.
Ramlau, R.
Vladimirov, V.
Cheng, Y.
Deng, X.
Bas, T.
Piperdi, B.
Halmos, B.
ANNALS OF ONCOLOGY, 2019, 30
[8] Impact of histology on the efficacy and safety of pembrolizumab (pembro) monotherapy for advanced urothelial carcinoma (UC) in the phase 3 KEYNOTE-045 and KEYNOTE-361 trials
Giannatempo, Patrizia
Machiels, Jean-Pascal H.
Sassa, Naoto
Arija, Jose Angel Arranz
Fujii, Yasuhisa
Su, Wen-Pin
Keam, Bhumsuk
Culine, Stephane
Shen, Ying-Chun
Munoz-Langa, Jose
Sarid, David Leonid
Aarts, Maureen J. B.
Calabro, Fabio
Rosenbaum, Eli
Goldman, Olesya
Moreno, Blanca Homet
Bavle, Abhishek Amar
Xu, Jin Zhi
Rha, Sun Young
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[9] Quantitative circulating tumor DNA (ctDNA) assessment in patients (pts) with advanced urothelial carcinoma (UC) treated with pembrolizumab (pembro) or platinum-based chemotherapy (chemo) from the phase 3 KEYNOTE-361 trial
Powles, Thomas
Chang, Wayne Yen-Hwa
Yamamoto, Yoshiaki
Munoz-Langa, Jose
Reyes, Felipe
Peer, Avivit
Yu, Evan Y.
Cohen, Graham
Lorch, Anja
Bavle, Abhishek
Moreno, Blanca Homet
Markensohn, Julia
Edmondson, Mackenzie
Chen, Cai
Cristescu, Razvan
Pena, Carol Elaine
Lunceford, Jared
Gunduz, Seyda
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[10] KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.
Gadgeel, Shirish M.
Garassino, Marina Chiara
Esteban, Emilio
Speranza, Giovanna
Felip, Enriqueta
Hochmair, Maximilian J.
Powell, Steven Francis
Cheng, Susanna Y.
Bischoff, Helge
Peled, Nir
Hui, Rina
Reck, Martin
Kurata, Takayasu
Garon, Edward B.
Boyer, Michael J.
Yang, Jing
Pietanza, Maria Catherine
Rodriguez-Abreu, Delvys
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →